Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.74 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 4/20 | 0.46 |
| ▸ | CES1 | P23141 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dodecane SCHEMBL3308504 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL2399914 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1614041 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Dodecane SCHEMBL1747351 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL1190938 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL9107982 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL11904142 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL276236 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Hexadecane SCHEMBL3291441 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 | |
| Heptane SCHEMBL18725336 | 1.00 | ALDH1A1 (0.74) | ALDH1A1LMNAHSD17B10FAAHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2024-05-23 | — | — | US | disclosed |
| US-11642348-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-113801138-A | Method for preparing lanimivir octanoate intermediate by one-pot method | 博瑞生物医药（苏州）股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-113801082-A | Preparation method of lanimivir octanoate | 博瑞生物医药（苏州）股份有限公司 | 2021-12-17 | — | — | CN | disclosed |
| CN-107428651-B | Liquid crystalline compound, liquid crystal composition, liquid crystal-encapsulated composite fiber, fiber aggregate, fiber composite, and liquid crystal display element | 捷恩智株式会社 | 2021-06-22 | — | — | CN | disclosed |
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-03-04 | — | — | US | disclosed |
| EP-3725314-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| CN-108129404-B | Synthesis method of chiral piperazinone derivative | 凯瑞斯德生化(苏州)有限公司 | 2020-05-01 | — | — | CN | disclosed |
| EP-2906537-B1 | SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2020-03-11 | — | — | EP | disclosed |
| CN-110041250-A | The benzene compound being substituted | EPIZYME股份有限公司 | 2019-07-23 | — | — | CN | disclosed |
| US-6218365-B1 | FOR TREATING OR PREVENTING A THROMBIN-RELATED DISEASE | AKZO NOBEL N.V. (NL) | 2001-04-17 | — | — | US | disclosed |
| EP-1012164-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 2000-06-28 | — | — | EP | disclosed |
| CN-1249736-A | Liquid-crystal compounds, liquid-crystal composition contg. same, and liquid-crystal display element contg. same | CHISSO CORP (JP) | 2000-04-05 | — | — | CN | disclosed |
| EP-0976703-A1 | LIQUID-CRYSTAL COMPOUNDS, LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME, AND LIQUID-CRYSTAL DISPLAY ELEMENT CONTAINING THE SAME | CHISSO CORPORATION (JP) | 2000-02-02 | — | — | EP | disclosed |
| EP-0956293-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1999-11-17 | — | — | EP | disclosed |
| CN-1212705-A | Serine protease inhibitors | AKZO NOBEL NV (NL) | 1999-03-31 | — | — | CN | disclosed |
| EP-0858464-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1998-08-19 | — | — | EP | disclosed |
| WO-1998007308-A2 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-02-26 | — | — | WO | disclosed |
| WO-1997031939-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997017363-A1 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060027-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | ALDH1A1 358/4885LMNA 1888/4885HSD17B10 1243/4885 |
| US-20240165121-A1 | SUBSTITUTED BENZENE COMPOUNDS | CYP1B1, TP53, VHL | ALDH1A1 358/4885LMNA 1888/4885HSD17B10 1243/4885 |
| US-11642348-B2 | Substituted benzene compounds | CYP1B1, TP53, VHL | ALDH1A1 358/4885LMNA 1888/4885HSD17B10 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.